

# Supporting Information

## Relay Catalysis: Combined Metal Catalyzed Oxidation and Asymmetric Iminium Catalysis for the Synthesis of Bi- and Tricyclic Chromenes

Magnus Rueping,\* Jeremy Dufour and Modhu Sudan Maji

*Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany*

<b>General information</b>	<b>S-2</b>
<b>General procedures</b>	<b>S-3</b>
<b>Description of the compounds</b>	<b>S-4</b>
<b>Copies of NMR Spectra and analytical chiral HPLC traces</b>	<b>S-14</b>

## General Information

Unless otherwise stated, all reagents were obtained from commercial suppliers. Organic solvents were routinely dried and/or distilled prior to use and stored over molecular sieves under argon. Solvents for chromatography were technical grade and distilled prior to use. Thin layer chromatography (TLC) was carried out on Merck aluminium support plates Silicagel 60 F<sub>254</sub>. Visualization was achieved under a UV mineral light. Column chromatography was performed using silicagel Merck 60 (particle size 0.2-0.063 mm). Proton NMR (<sup>1</sup>H NMR) spectra were recorded at 400 MHz on an Inova 400 spectrometer or at 300 MHz on a Mercury 300 spectrometer. Carbon NMR (<sup>13</sup>C) spectra were similarly recorded at 125 or 75 MHz, using a broadband decoupled mode with the multiplicities obtained using a JMOD or DEPT sequence. Proton and carbon NMR chemical shifts ( $\delta$ ) are reported in parts per million (ppm) relative to residual proton signals in CDCl<sub>3</sub> ( $\delta$  = 7.26, 77.16) or in CD<sub>2</sub>Cl<sub>2</sub> ( $\delta$  = 5.32, 54.00). Coupling constants ( $J$ ) are reported in Hertz (Hz) and refer to apparent multiplicities. The following abbreviations are used for the multiplicities: s: singlet, d: doublet, t: triplet, q: quartet, qu: quintet, m: multiplet, br: broad. Mass spectra (MS-EI, 70 eV) were conducted on GC-MS Shimadzu QP2010 (column: Equity®-5, length × I.D. 30 m × 0.25 mm, df 0.25  $\mu$ m, lot # 28089-U, Supelco). IR spectra were recorded on a Jasco FT/IR-420 spectrometer and are reported in terms of frequency of absorption (cm<sup>-1</sup>). Optical rotations were measured on a Perkin Elmer 241 polarimeter using 10 cm cells and the sodium D line (589 nm), in the solvent, at concentration and temperature indicated. The enantiomeric excesses were determined by HPLC analysis using a chiral stationary phase column (column, Daicel Co. Chiralpak AS-H, AD-H, OJ-H or Chiralcel IC, eluent: *n*-hexane/2-propanol). The chiral HPLC methods were calibrated with the corresponding racemic mixtures. Chemical yields refer to pure isolated substances. Melting points (m.p.) were recorded using Büchi B-540 melting point apparatus and are uncorrected.

## General procedures

### Procedures for starting materials:

TPAP was prepared following a literature procedure.<sup>1</sup> The starting propargyl alcohols **2** were prepared either by Sonogashira coupling using the corresponding aryl iodide and propargyl alcohol or by hydroxymethylation of the corresponding terminal alkynes via lithiation and subsequent reaction with paraformaldehyde.<sup>2</sup> The nitrostyrene derivatives **1** were prepared following a reported procedure.<sup>3</sup>

**General procedure I for the oxidative iminium-enamine cascade:** To a solution of propargyl alcohol **2** (0.60 mmol, 1.50 equiv) and NMO (0.64 mmol, 1.60 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (3.0 mL) were added TPAP (38 µmol, 7 mol%), nitrostyrene derivative **1** (0.40 mmol, 1.0 equiv) and diphenylprolinol TMS-ether organocatalyst **4** (80 µmol, 20 mol%). The resulting solution was stirred for 18h at room temperature under an argon atmosphere. The crude reaction mixture was directly charged on silica gel and purified by flash column chromatography (EtOAc/cyclohexane) to afford the pure desired products **3**.

Racemic products were synthesized according to the general procedure **I** by using pyrrolidine as catalyst.

**General procedure II for the preparation of the tricyclic compounds:** To a solution of (*R*)-4-(nitromethyl)-2-phenyl-4*H*-chromene-3-carbaldehyde **3a** (0.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) were added the corresponding cinnamaldehyde **5** (0.23 mmol, 1.5 equiv) and diphenylprolinol TMS-ether **4** (30 µmol, 20 mol%). The resulting solution was stirred for 48h at room temperature under argon atmosphere. NEt<sub>3</sub> (0.30 mmol, 2.0 equiv) was then added and the resulting mixture was stirred for further 18h. The crude reaction mixture was directly purified by preparative thin layer chromatography (EtOAc/cyclohexane or toluene) to afford the desired tricyclic products.

<sup>1</sup> V. Farmer, T. Welton, *Green Chemistry* 2002, **4**, 97-102.

<sup>2</sup> F. Kleinbeck, F. D. Toste, *J. Am. Chem. Soc.* 2009, **131**, 9178-9179.

<sup>3</sup> a) J. McNulty, J. A. Steere, S. Wolf, *Tetrahedron Lett.* 1998, **39**, 8013-8016; b) J.-T. Liu, C.-F. Yao, *Tetrahedron Lett.* 2001, **42**, 6147-6150.

## Description of the compounds

The absolute configuration of the tricyclic 4*H*-chromene compounds was unambiguously determined by X-ray crystallographic analysis of **6e** (Figure 1).<sup>4</sup> All three newly formed chiral centers possess the *R* configuration. It is worth pointing out that the nitro group lies *anti* to the aryl group, occupying the less sterically hindered position. This supports the proposed epimerization of the center  $\alpha$  to the nitro group towards the thermodynamically more stable product.






Figure. Molecular structure of compound **6e**.

### (R)-4-(Nitromethyl)-2-phenyl-4*H*-chromene-3-carbaldehyde **3a**

 The title compound was prepared following the general procedure **I** and isolated as a pale yellow solid in 81% yield.  
**m.p.** 118-122 °C. **1H NMR** (300 MHz, CDCl<sub>3</sub>)  $\delta$  9.50 (s, 1H), 7.59-7.36 (m, 5H), 7.29-7.16 (m, 2H), 7.16-7.04 (m, 2H), 4.72-4.38 (m, 3H). **13C NMR** (75 MHz, CDCl<sub>3</sub>)  $\delta$  190.4, 170.0, 150.8, 131.9, 130.8, 130.5, 129.5, 128.8, 128.7, 126.1, 119.9, 117.3, 111.7, 79.8, 32.4. **IR** (KBr, cm<sup>-1</sup>)  $\nu$  2919, 2862, 1724, 1635, 1580, 1548, 1489, 1364, 1290, 1259, 1218, 1181, 1112, 804, 761, 703. **MS** *m/z* (CI+) 296 ([M+H]<sup>+</sup>). **HPLC** (Chiraldak AS-H, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>) *t*<sub>major</sub> = 27.63 min; *t*<sub>minor</sub> = 38.2 min, *ee* = 95%.  $[\alpha]^{25}_D$  = +18.0 (*c* 0.5, CHCl<sub>3</sub>).

<sup>4</sup> J. Dufor, M. S. Maji, M. Bolte *Acta Crystallographica, Section E: Structure Reports Online* 2011, E67(11), o2844.


(R)-Methyl 4-(3-formyl-4-(nitromethyl)-4H-chromen-2-yl)benzoate 3b



The title compound was prepared following the general procedure **I** and isolated as a pale yellow solid in 86% yield.

**m.p.** 147-148 °C; **1H NMR** (300 MHz, CDCl<sub>3</sub>) δ 9.59 (s, 1H), 8.19 (d, J = 8.1 Hz, 2H), 7.70 (d, J = 8.1 Hz, 2H), 7.39-7.17 (m, 4H), 4.80-4.64 (m, 3H), 3.98 (s, 3H); **13C NMR** (75 MHz, CDCl<sub>3</sub>) δ 189.9, 168.6, 166.2, 150.7, 134.9, 133.1, 130.5, 129.9, 129.6, 128.6, 126.3, 119.6, 117.3, 112.5, 79.7, 52.7, 32.4. **MS m/z** (CI+) 354 ([M+H]<sup>+</sup>); **IR** (KBr, cm<sup>-1</sup>) ν 1723, 1650, 1629, 1608, 1578, 1549, 1489, 1365, 1281, 1258, 1216, 1188, 1109, 871, 761, 712. **HPLC** (Chiralpak AD-H, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.5 mL·min<sup>-1</sup>) t<sub>major</sub> = 22.98 min; t<sub>minor</sub> = 25.01 min, ee = 96%. [α]<sup>25</sup><sub>D</sub> = -7.0 (c 1.0, CHCl<sub>3</sub>).


(R)-4-(Nitromethyl)-2-(4-nitrophenyl)-4H-chromene-3-carbaldehyde 3c



The title compound was prepared following the general procedure **I** and isolated as a pale yellow solid in 77% yield.

**m.p.** 51-54 °C. **1H NMR** (300 MHz, CDCl<sub>3</sub>) δ 9.59 (s, 1H), 8.39 (d, J = 8.8 Hz, 2H), 7.83 (d, J = 8.8 Hz, 2H), 7.41-7.26 (m, 3H), 7.19 (dd, J = 8.2, 1.2 Hz, 1H), 4.82 (dd, J = 13.2, 6.9 Hz, 1H), 4.74-4.65 (m, 2H). **13C NMR** (75 MHz, CDCl<sub>3</sub>) δ 189.2, 167.0, 150.6, 149.8, 136.8, 131.5, 129.8, 128.7, 126.6, 124.0, 119.2, 117.3, 113.3, 79.7, 32.4. **MS m/z** (CI+) 341 ([M+H]<sup>+</sup>). **IR** (KBr, cm<sup>-1</sup>) ν 3108, 2860, 1736, 1657, 1545, 1521, 1489, 1348, 1291, 1259, 1217, 1179, 1108, 853, 759, 704. **HPLC** (Chiralcel IC, 0.46 x 25 cm, *n*-hexane/2-propanol = 50/50, flow rate = 0.6 mL·min<sup>-1</sup>) t<sub>major</sub> = 81.31 min; t<sub>minor</sub> = 94.78 min, ee = 95%. [α]<sup>25</sup><sub>D</sub> = -15.2 (c 0.7, CHCl<sub>3</sub>).

(R)-2-(4-Bromophenyl)-4-(nitromethyl)-4H-chromene-3-carbaldehyde 3d




The title compound was prepared following the general procedure **I** and isolated as a pale yellow solid in 80% yield.

**m.p.** 95-98 °C. **1H NMR** (300 MHz, CDCl<sub>3</sub>) δ 9.59 (s, 1H), 7.68 (d, J = 8.7 Hz, 2H), 7.50 (d, J = 8.7 Hz, 2H), 7.35 (ddd, J = 8.2, 7.2, 1.9 Hz, 1H), 7.31 (dd, J = 7.8, 1.9 Hz, 1H), 7.24 (ddd, J = 7.8, 7.2, 1.2 Hz, 1H), 7.18 (dd, J = 8.0, 1.2 Hz, 1H), 4.75 (dd, J = 9.5, 4.7 Hz, 1H), 4.70 (dd, J = 4.7, 3.0 Hz, 1H), 4.65 (dd, J = 9.5, 3.0 Hz, 1H). **13C NMR** (75 MHz, CDCl<sub>3</sub>) δ 189.8, 168.7, 150.7, 132.2, 131.9, 129.7, 129.6, 128.6, 126.7, 126.3, 119.7, 117.3, 112.0, 79.8, 32.4. **MS m/z** (CI+)

376, 374 ( $[M+H]^+$ ). **IR** (KBr,  $\text{cm}^{-1}$ )  $\nu$  3022, 2860, 1785, 1725, 1669, 1550, 1422, 1384, 1314, 1274, 1216, 1124, 1097, 1048, 990, 907, 757. **HPLC** (Chiralpak AS-H, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>)  $t_{\text{major}} = 31.47$  min;  $t_{\text{minor}} = 52.36$  min, *ee* = 97%.  $[\alpha]^{25}_{\text{D}} = -7.4$  (*c* 1.2, CHCl<sub>3</sub>).


**(R)-2-(4-*tert*-Butylphenyl)-4-(nitromethyl)-4*H*-chromene-3-carbaldehyde 3e**



The title compound was prepared following the general procedure **I** and isolated as a pale yellow solid in 80% yield.

**m.p.** 54-58 °C. **<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>)  $\delta$  9.64 (s, 1H), 7.59-7.52 (m, 4H), 7.37-7.29 (m, 2H), 7.25-7.18 (m, 2H), 4.75-4.62 (m, 3H), 1.38 (s, 9H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>)  $\delta$  190.5, 170.1, 155.6, 150.9, 130.3, 129.4, 128.7, 127.9, 126.0, 125.8, 120.1, 117.3, 111.4, 79.8, 35.2, 32.4, 31.3. **IR** (KBr, cm<sup>-1</sup>)  $\nu$  2963, 2868, 1655, 1633, 1580, 1550, 1487, 1461, 1396, 1368, 1262, 1221, 1184, 1116, 843, 758. **MS** *m/z* (CI+) 352 ( $[M+H]^+$ ). **HPLC** (Chiralcel IC, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>)  $t_{\text{major}} = 22.66$  min;  $t_{\text{minor}} = 55.73$  min, *ee* = 95%.  $[\alpha]^{25}_{\text{D}} = -20.1$  (*c* 1.4, CHCl<sub>3</sub>).


**(R)-2-(4-Methoxyphenyl)-4-(nitromethyl)-4*H*-chromene-3-carbaldehyde 3f**



The title compound was prepared following the general procedure **I** and isolated as a pale yellow solid in 70% yield.

**m.p.** 103-106 °C. **<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>)  $\delta$  9.61 (s, 1H), 7.58 (d, *J* = 9.0 Hz, 2H), 7.37-7.29 (m, 2H), 7.24-7.19 (m, 2H), 7.02 (d, *J* = 9.0 Hz, 2H), 4.73-4.59 (m, 3H), 3.89 (s, 3H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>)  $\delta$  190.3, 169.9, 162.7, 150.8, 132.3, 129.4, 128.7, 126.0, 122.9, 120.2, 117.2, 114.2, 110.8, 79.8, 55.7, 32.4. **IR** (KBr, cm<sup>-1</sup>)  $\nu$  3286, 3070, 2861, 1649, 1605, 1536, 1507, 1456, 1395, 1365, 1308, 1247, 1170, 1112, 1019, 841. **MS** *m/z* (CI+) 326 ( $[M+H]^+$ ). **HPLC** (Chiralcel IC, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>)  $t_{\text{major}} = 41.36$  min;  $t_{\text{minor}} = 107.26$  min, *ee* = 96%.  $[\alpha]^{25}_{\text{D}} = -20.1$  (*c* 2.1, CHCl<sub>3</sub>).

**(R)-2-(3-Methoxyphenyl)-4-(nitromethyl)-4*H*-chromene-3-carbaldehyde 3g**




The title compound was prepared following the general procedure **I** and isolated as a pale yellow solid in 84% yield.

**m.p.** 117-120 °C. **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>)  $\delta$  9.59 (s, 1H),

7.42-7.36 (m, 1H), 7.34-7.24 (m, 2H), 7.22-7.13 (m, 3H), 7.13-7.05 (m, 2H), 4.71-4.58 (m, 3H), 3.84 (s, 3H). **<sup>13</sup>C NMR** (100 MHz, CDCl<sub>3</sub>) δ 190.3, 169.6, 159.7, 150.7, 131.9, 129.8, 129.4, 128.6, 126.0, 123.0, 119.8, 117.5, 117.3, 115.5, 111.7, 79.8, 55.7, 32.5. **MS m/z** (CI+) 326 ([M+H]<sup>+</sup>). **IR** (KBr, cm<sup>-1</sup>) ν 3024, 2914, 2860, 1782, 1725, 1659, 1578, 1550, 1488, 1425, 1365, 1311, 1271, 1230, 1096, 1045, 991, 879, 758. **HPLC** (Chiralcel IC, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>) t<sub>major</sub> = 31.47 min; t<sub>minor</sub> = 72.87 min, ee = 96%. [α]<sup>25</sup><sub>D</sub> = +2.0 (c 0.5, CHCl<sub>3</sub>).


**(R)-2-(2-Methoxyphenyl)-4-(nitromethyl)-4*H*-chromene-3-carbaldehyde 3h**



The title compound was prepared following the general procedure I and isolated as a pale gummy solid in 49% yield.

**<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>) δ 9.38 (s, 1H), 7.55-7.49 (m, 1H), 7.45-7.42 (m, 1H), 7.35-7.28 (m, 2H), 7.23-7.17 (m, 1H), 7.14-7.01 (m, 3H), 4.74-4.61 (m, 3H), 3.83 (s, 3H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ 190.7, 157.9, 151.1, 132.9, 131.8, 129.3, 128.6, 125.8, 120.7, 120.1, 120.0, 117.3, 112.5, 111.6, 79.6, 55.9, 32.3. **IR** (KBr, cm<sup>-1</sup>) ν 2937, 2847, 1639, 1581, 1547, 1489, 1459, 1433, 1365, 1299, 1246, 1217, 1177, 1103, 1021, 755. **MS m/z** (CI+) 326 ([M+H]<sup>+</sup>). **HPLC** (Chiralcel IC, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>) t<sub>major</sub> = 18.07 min; t<sub>minor</sub> = 29.34 min, ee = 91%. [α]<sup>25</sup><sub>D</sub> = -26.1 (c 1.2, CHCl<sub>3</sub>).


**(R)-4-(Nitromethyl)-2-(thiophen-2-yl)-4*H*-chromene-3-carbaldehyde 3i**



The title compound was prepared following the general procedure I and isolated as a pale yellow solid in 92% yield.

**m.p.** 138-140 °C. **<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>) δ 9.81 (s, 1H), 7.60 (dd, *J* = 5.1, 1.2 Hz, 1H), 7.46 (dd, *J* = 3.7, 1.2 Hz, 1H), 7.30-7.08 (m, 5H), 4.67-4.61 (m, 1H), 4.57-4.51 (m, 2H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ 189.3, 163.1, 150.5, 133.8, 132.3, 131.8, 129.5, 128.6, 127.9, 126.1, 120.1, 117.3, 111.7, 79.6, 32.5. **MS m/z** (CI+) 302 ([M+H]<sup>+</sup>). **IR** (KBr, cm<sup>-1</sup>) ν 2858, 1727, 1646, 1602, 1538, 1486, 1423, 1369, 1296, 1227, 1182, 1105, 879, 853, 794, 764, 719. **HPLC** (Chiralcel IC, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>) t<sub>major</sub> = 41.00 min; t<sub>minor</sub> = 92.48 min, ee = 96%. [α]<sup>25</sup><sub>D</sub> = -11.1 (c 0.7, CHCl<sub>3</sub>).


**(R)-2-Cyclohexenyl-4-(nitromethyl)-4H-chromene-3-carbaldehyde 3j**



The title compound was prepared following the general procedure I and isolated as a white solid in 90% yield.

**m.p.** 127-130 °C. **<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>) δ 9.65 (s, 1H), 7.23 (ddd, J = 8.1, 7.1, 1.8 Hz, 2H), 7.18 (dd, J = 7.7, 1.8 Hz, 1H), 7.10 (ddd, J = 7.7, 7.1, 1.2 Hz, 1H), 7.03 (dd, J = 8.1, 1.2 Hz, 1H), 6.27-6.08 (m, 1H), 4.57-4.45 (m, 3H), 2.58-2.39 (m, 1H), 2.28-2.16 (m, 2H), 2.11-1.97 (m, 1H), 1.76-1.53 (m, 4H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ 189.5, 173.3, 150.6, 139.8, 129.9, 129.3, 128.6, 125.7, 119.9, 117.0, 111.4, 79.7, 32.3, 25.9, 25.8, 22.0, 21.7. **MS m/z** (CI+) 300 ([M+H]<sup>+</sup>). **IR** (KBr, cm<sup>-1</sup>) ν 2934, 2863, 1725, 1642, 1576, 1544, 1488, 1364, 1289, 1237, 1175, 1116, 922, 844, 793, 759, 710. **HPLC** (Chiralpak AS-H, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>) t<sub>major</sub> = 18.18 min; t<sub>minor</sub> = 25.88 min, ee = 99%. [α]<sup>25</sup><sub>D</sub> = -86.2 (c 0.7, CHCl<sub>3</sub>).


**(R)-2-Cyclohexyl-4-(nitromethyl)-4H-chromene-3-carbaldehyde 3k**



The title compound was prepared following the general procedure I and isolated as a pale yellow oil in 95% yield.

**<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>) δ 10.09 (s, 1H), 7.37-7.25 (m, 2H), 7.22 (ddd, J = 8.0, 7.6, 1.0 Hz, 2H), 7.14 (dd, J = 8.1, 1.0 Hz, 1H), 4.59 (m, 3H), 3.33 – 3.21 (m, 1H), 1.98-1.74 (m, 6H), 1.52-1.25 (m, 4H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ 187.5, 176.1, 150.5, 129.2, 128.4, 125.7, 119.8, 116.8, 109.7, 79.7, 38.7, 31.9, 30.3, 29.9, 26.0, 25.8, 25.6. **MS m/z** (CI+) 302 ([M+H]<sup>+</sup>). **IR** (KBr, cm<sup>-1</sup>) ν 2930, 2854, 1715, 1653, 1631, 1579, 1542, 1452, 1364, 1232, 1172, 1008, 822, 759. **HPLC** (Chiralpak AS-H, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>) t<sub>major</sub> = 23.90 min; t<sub>minor</sub> = 18.44 min, ee = 97%. [α]<sup>25</sup><sub>D</sub> = -17.6 (c 0.5, CHCl<sub>3</sub>).

**(R)-2-tert-Butyl-4-(nitromethyl)-4H-chromene-3-carbaldehyde 3l**




The title compound was prepared following the general procedure I and isolated as a pale yellow solid in 96% yield.

**m.p.** 94-98 °C. **<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>) δ 10.4 (s, 1H), 7.31-7.07 (m, 4H), 4.69 (dd, J = 6.3 Hz, 4.5 Hz, 1H), 4.50-4.40 (m, 2H), 1.50 (s, 9H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ 188.7, 178.7, 150.7, 129.1, 128.2, 125.8, 120.2, 116.6, 110.5, 80.0, 39.0, 32.6, 31.2. **IR** (KBr, cm<sup>-1</sup>) ν 3046, 2970, 2894, 1642, 1573, 1538, 1481,

1458, 1396, 1360, 1223, 1182, 1142, 943, 863, 758. **MS**  $m/z$  (CI+) 276 ([M+H]<sup>+</sup>). **HPLC** (Chiraldak AS-H, 0.46 x 25 cm, *n*-hexane/2-propanol = 80/20, flow rate = 0.6 mL·min<sup>-1</sup>)  $t_{\text{major}} = 14.69$  min;  $t_{\text{minor}} = 17.18$  min, *ee* = 98%.  $[\alpha]^{25}_{\text{D}} = -55.5$  (*c* 1.1, CHCl<sub>3</sub>).


**(R)-2-((tert-Butyldimethylsilyloxy)methyl)-4-(nitromethyl)-4*H*-chromene-3-carbaldehyde **3m****



The title compound was prepared following the general procedure **I** and isolated as a pale yellow oil in 53% yield.

**<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>)  $\delta$  10.18 (s, 1H), 7.33-7.14 (m, 3H), 7.09 (d, *J* = 8.1 Hz, 1H), 4.78 (d, *J* = 13.9 Hz, 1H), 4.67 (d, *J* = 13.9 Hz, 1H), 4.68-4.53 (m, 3H), 0.92 (s, 9H), 0.16 (s, 6H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>)  $\delta$  188.7, 169.0, 150.3, 129.4, 128.6, 126.0, 119.8, 117.1, 112.2, 79.4, 60.5, 31.9, 25.9, 18.4, -5.1. **MS**  $m/z$  (CI+) 364 ([M+H]<sup>+</sup>). **IR** (KBr, cm<sup>-1</sup>)  $\nu$  2928, 2858, 1739, 1644, 1522, 1461, 1378, 1232, 1174, 1098, 1072, 966, 833, 759, 702. **HPLC** (Chiraldak OJ-H, 0.46 x 25 cm, *n*-hexane/2-propanol = 96/4, flow rate = 0.6 mL·min<sup>-1</sup>)  $t_{\text{major}} = 29.43$  min;  $t_{\text{minor}} = 33.60$  min, *ee* = 92%.  $[\alpha]^{25}_{\text{D}} = +4.0$  (*c* 0.3, CHCl<sub>3</sub>).


**(R)-6-Methoxy-4-(nitromethyl)-2-phenyl-4*H*-chromene-3-carbaldehyde **3n****



The title compound was prepared following the general procedure **I** and isolated as a white solid in 74% yield.

**m.p.** 123-130 °C. **<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>)  $\delta$  9.59 (s, *J* = 1.4 Hz, 1H), 7.66-7.45 (m, 5H), 7.13 (d, *J* = 8.9 Hz, 1H), 6.90-6.84 (m, 1H), 6.79 (d, *J* = 2.9 Hz, 1H), 4.78-4.59 (m, 3H), 3.81 (s, *J* = 1.4 Hz, 3H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>)  $\delta$  190.4, 170.1, 157.4, 144.9, 131.8, 130.9, 130.4, 128.8, 120.7, 118.2, 115.3, 112.6, 110.8, 79.6, 55.9, 32.8. **MS**  $m/z$  (CI+) 326 ([M+H]<sup>+</sup>). **IR** (KBr, cm<sup>-1</sup>)  $\nu$  3020, 2918, 2850, 1651, 1630, 1586, 1550, 1498, 1430, 1362, 1257, 1213, 1032, 756. **HPLC** (Chiralcel IC, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>)  $t_{\text{major}} = 30.49$  min;  $t_{\text{minor}} = 38.22$  min, *ee* = 94%.  $[\alpha]^{25}_{\text{D}} = +46.3$  (*c* 0.3, CHCl<sub>3</sub>).

**(R)-7-Methoxy-4-(nitromethyl)-2-phenyl-4*H*-chromene-3-carbaldehyde **3o****




The title compound was prepared following the general procedure **I** and isolated as a pale yellow solid in 74% yield.

**m.p.** 120-127 °C. **<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>)  $\delta$  9.60 (s, 1H), 7.65-7.35 (m, 5H), 7.20 (d, *J* = 8.5 Hz, 1H), 6.76 (dd, *J* = 8.5; 2.6 Hz, 1H), 6.72 (d, *J* = 2.6 Hz, 1H), 4.74-4.60 (m, 3H), 3.82 (s,

3H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ 190.5, 169.8, 160.4, 151.5, 131.9, 130.8, 130.4, 129.2, 128.8, 112.8, 112.1, 111.6, 102.3, 79.9, 55.7, 32.0. **MS m/z** (CI+) 326 ([M+H]<sup>+</sup>). **IR** (KBr, cm<sup>-1</sup>) ν 2924, 2859, 1725, 1639, 1577, 1542, 1505, 1441, 1361, 1331, 1167, 1106, 1025, 938, 829, 746, 695. **HPLC** (Chiralcel IC, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>) t<sub>major</sub> = 33.21 min; t<sub>minor</sub> = 67.23 min, ee = 97%. [α]<sup>25</sup><sub>D</sub> = +60.0 (c 0.6, CHCl<sub>3</sub>).


**(R)-6-Bromo-4-(nitromethyl)-2-phenyl-4H-chromene-3-carbaldehyde 3p**



The title compound was prepared following the general procedure I and isolated as a yellow solid in 76% yield.

**m.p.** 188-190 °C. **<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>) δ 9.58 (s, 1H), 7.62-7.41 (m, 7H), 7.12-7.03 (m, 1H), 4.81-4.73 (m, 1H), 4.67-4.61 (m, 2H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ 190.2, 169.6, 150.0, 132.5, 132.1, 131.3, 130.4, 128.9, 122.1, 119.0, 118.4, 111.2, 79.5, 32.2. **MS m/z** (CI+) 374, 376 ([M+H]<sup>+</sup>). **IR** (KBr, cm<sup>-1</sup>) ν 2879, 1738, 1649, 1628, 1573, 1537, 1480, 1424, 1358, 1255, 1217, 1178, 1126, 891, 807, 726, 695. **HPLC** (Chiraldcel AS-H, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>) t<sub>major</sub> = 31.12 min; t<sub>minor</sub> = 57.55 min, ee = 95%. [α]<sup>25</sup><sub>D</sub> = +87.8 (c 0.7, CHCl<sub>3</sub>).


**(R)-6-Methyl-4-(nitromethyl)-2-phenyl-4H-chromene-3-carbaldehyde 3q**



The title compound was prepared following the general procedure I and isolated as a white solid in 84% yield.

**m.p.** 153-155 °C. **<sup>1</sup>H NMR** (300 MHz, CDCl<sub>3</sub>) δ 9.59 (s, 1H), 7.66-7.45 (m, 5H), 7.19-7.03 (m, 3H), 4.78-4.59 (m, 3H), 2.36 (s, 3H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ 190.5, 170.1, 148.8, 135.9, 131.8, 130.9, 130.5, 130.1, 128.8, 119.6, 117.0, 111.6, 79.8, 32.4, 21.0. **MS m/z** (CI+) 310 ([M+H]<sup>+</sup>). **IR** (KBr, cm<sup>-1</sup>) ν 2863, 2070, 1732, 1643, 1621, 1583, 1547, 1494, 1423, 1358, 1259, 1196, 1124, 815, 759, 701. **HPLC** (Chiralcel IC, 0.46 x 25 cm, *n*-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>) t<sub>major</sub> = 29.57 min; t<sub>minor</sub> = 47.34 min, ee = 96%. [α]<sup>25</sup><sub>D</sub> = +43.0 (c 0.6, CHCl<sub>3</sub>).

**(R)-8-Methyl-4-(nitromethyl)-2-phenyl-4H-chromene-3-carbaldehyde 3r**




The title compound was prepared following the general procedure I and isolated as a pale yellow solid in 71% yield. **m.p.** 117-120 °C. **<sup>1</sup>H NMR**

(300 MHz, CDCl<sub>3</sub>) δ 9.63 (s, 1H), 7.68-7.46 (m, 5H), 7.22-7.08 (m, 3H), 4.75-4.60 (m, 3H), 2.38 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 190.4, 169.9, 149.2, 132.0, 131.0, 130.9, 130.6, 129.0, 126.7, 126.2, 125.6, 119.7, 111.7, 80.0, 32.6, 16.0. MS m/z (CI+) 310 ([M+H]<sup>+</sup>). IR (KBr, cm<sup>-1</sup>) ν 2920, 2854, 1735, 1653, 1588, 1549, 1468, 1445, 1371, 1271, 1188, 1078, 910, 780, 734, 701. HPLC (Chiralpak AS-H, 0.46 x 25 cm, n-hexane/2-propanol = 70/30, flow rate = 0.6 mL·min<sup>-1</sup>) t<sub>major</sub> = 21.69 min; t<sub>minor</sub> = 27.15 min, ee = 77%. [α]<sup>25</sup><sub>D</sub> = +75.0 (c 0.6, CHCl<sub>3</sub>).


(9R,10R,10aR)-10-Nitro-6,9-diphenyl-10,10a-dihydro-9H-benzo[c]chromene-8-carbaldehyde

**6a**



The title compound was prepared following the general procedure **II** and isolated as a pale yellow solid in 77% yield. m.p. 132-136 °C. <sup>1</sup>H NMR (300 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 9.44 (s, 1H), 7.71-7.65 (m, 2H), 7.63 (s, 1H), 7.61-7.54 (m, 3H), 7.48-7.20 (m, 6H), 7.20-7.02 (m, 3H), 5.46 (dd, J = 3.1, 1.6 Hz, 1H), 4.75 (brs, 1H), 4.33 (d, J = 3.1 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 191.5, 157.1, 151.4, 145.5, 139.8, 133.2, 133.0, 131.1, 130.1, 129.8, 129.5, 129.2, 128.7, 128.6, 126.2, 125.2, 118.7, 117.8, 105.2, 86.1, 43.3, 32.6. MS m/z (EI+) 410 ([M+H]<sup>+</sup>). HRMS m/z (ES+) calcd for C<sub>26</sub>H<sub>20</sub>NO<sub>4</sub> ([M+H]<sup>+</sup>) 410.13868, found 410.13870. IR (KBr, cm<sup>-1</sup>) ν 2919, 2851, 1734, 1676, 1548, 1454, 1376, 1238, 1163, 1115, 1075, 950, 765, 704. [α]<sup>25</sup><sub>D</sub> = -90.3 (c 1.4, CHCl<sub>3</sub>).


(9R,10R,10aR)-9-(4-Methoxyphenyl)-10-nitro-6-phenyl-10,10a-dihydro-9H-benzo[c]chromene-8-carbaldehyde 6b



The title compound was prepared following general procedure **II** and isolated as a yellow solid in 83% yield. m.p. 119-123 °C. <sup>1</sup>H NMR (300 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 9.43 (s, J = 10.2 Hz, 1H), 7.74-7.65 (m, 2H), 7.63-7.51 (m, 4H), 7.33-7.03 (m, 6H), 6.93 (d, J = 8.8 Hz, 2H), 5.42 (dd, J = 3.4, 1.7 Hz, 1H), 4.69 (brs, 1H), 4.34 (d, J = 3.1 Hz, 1H), 3.80 (s, J = 2.3 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 191.5, 160.0, 156.9, 151.4, 145.2, 133.5, 133.0, 131.7, 131.1, 130.1, 129.8, 129.4, 129.2, 126.2, 125.2, 118.8, 117.8, 115.1, 105.2, 86.3, 55.9, 42.6, 32.5. MS m/z


(EI+) 440 ( $[M+H]^+$ ). **HRMS**  $m/z$  (EI+) calcd for  $C_{27}H_{22}NO_5$  ( $[M+H]^+$ ) 440.14925, found 440.14932. **IR** (KBr,  $\text{cm}^{-1}$ )  $\nu$  2194, 2121, 1732, 1673, 1607, 1545, 1506, 1452, 1364, 1303, 1245, 1161, 1118, 1074, 1028, 949, 825, 759, 697.  $[\alpha]^{25}_D = -125.2$  ( $c$  1.6,  $\text{CHCl}_3$ ).

(9*R*,10*R*,10a*R*)-10-Nitro-9-(4-nitrophenyl)-6-phenyl-10,10a-dihydro-9*H*-benzo[*c*]chromene-8-carbaldehyde 6c




The title compound was prepared following general procedure **II** and isolated as a yellow solid in 81% yield. **m.p.** 175-178 °C. **<sup>1</sup>H NMR** (300 MHz,  $\text{CD}_2\text{Cl}_2$ )  $\delta$  9.45 (s, 1H), 8.26 (d,  $J = 8.8$  Hz, 2H), 7.70 (s, 1H), 7.70-7.64 (m, 2H), 7.62-7.56 (m, 3H), 7.53 (d,  $J = 8.8$  Hz, 2H), 7.36-7.25 (m, 1H), 7.14 (dd,  $J = 6.6, 1.3$  Hz, 2H), 7.13-7.07 (m, 1H), 5.44 (dd,  $J = 3.2, 1.5$  Hz, 1H), 4.85 (brs, 1H), 4.29 (d,  $J = 3.2$  Hz, 1H). **<sup>13</sup>C NMR** (75 MHz,  $\text{CD}_2\text{Cl}_2$ )  $\delta$  191.2, 157.9, 151.3, 148.2, 146.9, 146.2, 132.8, 132.1, 131.3, 130.7, 130.1, 129.9, 129.7, 129.3, 126.2, 125.4, 124.9, 118.0, 104.4, 85.4, 43.0, 32.8. **MS**  $m/z$  (EI+) 454 (M). **HRMS**  $m/z$  (EI+) calcd for  $C_{26}H_{18}NO_4$  ( $[M-\text{NO}_2]^+$ ) 408.12303, found 408.12392. **IR** (KBr,  $\text{cm}^{-1}$ )  $\nu$  2920, 2851, 1672, 1627, 1604, 1577, 1548, 1518, 1346, 1261, 1230, 1163, 1113, 1076, 907, 858, 828, 762, 728.  $[\alpha]^{25}_D = -191.3$  ( $c$  1.5,  $\text{CHCl}_3$ ).

(9*R*,10*R*,10a*R*)-9-(4-Bromophenyl)-10-nitro-6-phenyl-10,10a-dihydro-9*H*-benzo[*c*]chromene-8-carbaldehyde 6d




The title compound was prepared following general procedure **II** and isolated as a pale yellow solid in 78% yield. **m.p.** 110-113 °C. **<sup>1</sup>H NMR** (300 MHz,  $\text{CD}_2\text{Cl}_2$ )  $\delta$  9.40 (s, 1H), 7.69-7.64 (m, 2H), 7.63 (s, 1H), 7.61-7.47 (m, 5H), 7.31-7.24 (m, 1H), 7.22 (d,  $J = 8.4$  Hz, 2H), 7.19-7.06 (m, 3H), 5.40 (dd,  $J = 3.4, 1.5$  Hz, 1H), 4.70 (brs, 1H), 4.29 (d,  $J = 3.1$  Hz, 1H). **<sup>13</sup>C NMR** (75 MHz,  $\text{CD}_2\text{Cl}_2$ )  $\delta$  191.3, 157.35, 151.4, 145.7, 139.0, 132.9, 132.7, 131.2, 130.5, 130.4, 130.1, 129.6, 129.3, 126.2, 125.3, 122.6, 118.4, 117.9, 104.9, 85.8, 42.7, 32.6 **MS**  $m/z$  (EI+) 487; 489 (M). **HRMS**  $m/z$  (EI+) calcd for  $C_{26}H_{18}NO_4^{79}\text{Br}$  ([M] 487.04137, found 487.04178. **IR** (KBr,  $\text{cm}^{-1}$ )  $\nu$  2919, 2851, 1907, 1733, 1676, 1628, 1545, 1457, 1373, 1236, 1161, 1165, 1117, 1074, 1012, 951, 821, 762, 706.  $[\alpha]^{25}_D = -284.0$  ( $c$  0.5,  $\text{CHCl}_3$ ).

(9*R*,10*R*,10a*R*)-9-(2-Bromophenyl)-10-nitro-6-phenyl-10,10a-dihydro-9*H*-benzo[*c*]chromene-8-carbaldehyde 6e




The title compound was prepared following general procedure **II** and isolated as a pale yellow solid in 85% yield. **m.p.** 196–199 °C. **<sup>1</sup>H NMR** (400 MHz, CDCl<sub>3</sub>) δ 9.45 (s, 1H), 7.72 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.68 (s, 1H), 7.67–7.63 (m, 2H), 7.59–7.54 (m, 3H), 7.28–7.16 (m, 5H), 7.11 (td, *J* = 7.5, 1.2 Hz, 1H), 7.06 (dd, *J* = 8.2, 1.2 Hz, 1H), 7.02 (dd, *J* = 7.5, 1.7 Hz, 1H), 5.49 (dd, *J* = 3.3, 1.4 Hz, 1H), 5.10 (brs, 1H), 4.24 (d, *J* = 3.3 Hz, 1H). **<sup>13</sup>C NMR** (75 MHz, CDCl<sub>3</sub>) δ 190.8, 157.0, 150.9, 145.8, 137.9, 134.2, 132.8, 132.4, 130.8, 129.8, 129.7, 129.7, 129.2, 128.8, 128.0, 126.2, 125.0, 124.8, 117.5, 117.3, 104.3, 83.5, 42.3, 32.7. **MS** *m/z* (EI+) 487; 489 (M). **HRMS** *m/z* (EI+) calcd for C<sub>26</sub>H<sub>18</sub>NO<sub>4</sub><sup>79</sup>Br ([M]) 487.04137, found 487.04142. **IR** (KBr, cm<sup>−1</sup>) ν 2327, 2070, 1733, 1675, 1609, 1574, 1544, 1489, 1455, 1366, 1258, 1230, 1165, 1117, 1072, 1020, 947, 830, 761, 696. [α]<sup>25</sup><sub>D</sub> = +58.0 (*c* 2.9, CHCl<sub>3</sub>).

Compound 3a




### Compound 3a


Data file: JD-98rac\_ASH\_7030\_flow06\_6565.DATA  
Method: HPLC1\_ASH\_7030\_flow06\_acq\_50  
Date: 18.06.2010 20:11:48





Data file: JD-114\_ASH\_7030\_flow06\_848961261.DATA  
Method: HPLC1\_ASH\_7030\_flow06\_acq\_50  
Date: 05.07.2010 21:31:59




Compound 3b



### Compound 3b




Compound 3c




### Compound 3c


Data file: JD-174rac\_IC\_5050\_flow07\_49644.DATA  
Method: HPLC1\_IC\_5050\_flow0.7\_acq\_130  
Date: 12.08.2010 17:22:46



Data file: JD-177\_IC\_5050\_flow07\_4524.DATA  
Method: HPLC1\_IC\_5050\_flow0.7\_acq\_130  
Date: 13.08.2010 10:08:06




Compound 3d




### Compound 3d


Data file: JD-134ra\_ASH\_7030\_flow06\_230021.DATA  
Method: HPLC1\_ASH\_7030\_flow06\_acq\_90  
Date: 06.08.2010 20:59:21



Data file: JD-161b\_ASH\_7030\_flow06\_989854341.DATA  
Method: HPLC1\_ASH\_7030\_flow06\_acq\_90  
Date: 06.08.2010 15:31:37




Compound 3e




### Compound 3e


Data file: MM-124\_IC\_7030\_flow06\_251.DATA  
Method: HPLC1\_IC\_7030\_flow06\_acq\_120  
Date: 28.08.2010 15:32:27



Data file: MM-224\_IC\_7030\_flow06\_25199.DATA  
Method: HPLC1\_IC\_7030\_flow06\_acq\_120  
Date: 30.08.2010 17:30:25




Compound 3f




### Compound 3f


Data file: MM-120r\_IC\_7030\_flow06\_1101.DATA  
Method: HPLC1\_IC\_7030\_flow06\_acq\_120  
Date: 12.08.2010 02:52:33





Data file: MM-177\_IC\_7030\_flow06\_12133.DATA  
Method: HPLC1\_IC\_7030\_flow06\_acq\_120  
Date: 10.08.2010 20:19:57




Compound 3g





## Compound 3g




Compound 3h



### Compound 3h




Compound 3i




### Compound 3i


Data file: JD-191rac\_IC\_7030\_flow06\_61919616.DATA  
Method: HPLC1\_IC\_7030\_flow06\_aqc\_120  
Date: 26.08.2010 14:38:27



Data file: JD-194\_IC\_7030\_flow06\_595.DATA  
Method: HPLC1\_IC\_7030\_flow06\_aqc\_120  
Date: 31.08.2010 18:04:03




Compound 3j




### Compound 3j


Data file: JD-162rac\_ASH\_7030\_flow06\_452424.DATA  
Method: HPLC1\_ASH\_7030\_flow06\_acq\_60  
Date: 04.08.2010 17:43:57



Data file: JD-163\_ASH\_7030\_flow06\_4241887.DATA  
Method: HPLC1\_ASH\_7030\_flow06\_acq\_60  
Date: 05.08.2010 10:27:40




Compound 3k




### Compound 3k


Data file: JD-133\_ASH\_7030\_flow06\_424.DATA  
Method: HPLC1\_ASH\_7030\_flow06\_acq\_50  
Date: 19.07.2010 09:48:06





Data file: JD-144\_ASH\_7030\_flow06\_619189189.DATA  
Method: HPLC1\_ASH\_7030\_flow06\_acq\_50  
Date: 22.07.2010 17:19:07




Compound 3l



## Compound 3l




Compound 3m




### Compound 3m


Method: HPLC1\_OJH\_964\_flow06\_acq00  
Date: 18.07.2010 18:29:48




Method: HPLC1\_OJH\_964\_flow06\_acq00  
Date: 06.08.2010 13:02:51




Compound 3n




### Compound 3n





Data file: JD-156\_IC\_7030\_flow06\_9595.DATA  
Method: HPLC1\_IC\_7030\_flow06\_acq\_120  
Date: 29.07.2010 17:02:33





Compound 3o





## Compound 3o




Compound 3p



## Compound 3p




Compound 3q




## Compound 3q


Data file: JD-187rac\_IC\_7030\_flow06\_151510.DATA  
Method: HPLC1\_IC\_7030\_flow06\_aqc\_120  
Date: 19.08.2010 23:06:59




Data file: JD-193\_IC\_7030\_flow06\_4111561.DATA  
Method: HPLC1\_IC\_7030\_flow06\_aqc\_120  
Date: 26.08.2010 18:41:21




Compound 3r




### Compound 3r




Data file: JD-227\_ASH\_7030\_flow06\_95956.DATA  
Method: HPLC1\_ASH\_7030\_flow06\_acq\_50  
Date: 21.09.2010 17:07:33




Compound 6a




Compound **6b**



Compound 6c



Compound **6d**



Compound **6e**

